A New Pediatric Precision Medicine Center is Opening in Utah
source: pixabay.com

A New Pediatric Precision Medicine Center is Opening in Utah

A new precision medicine center, specifically for pediatrics, has launched in Utah. This new center is the result of collaborative efforts from the Intermountain Primary Children's Hospital, Intermountain Precision Genomics,…

Continue Reading A New Pediatric Precision Medicine Center is Opening in Utah
Lupus Nephritis Patients Should be Excited About the Results of This Phase 3 Trial
source: pixabay.com

Lupus Nephritis Patients Should be Excited About the Results of This Phase 3 Trial

According to a story from BioPortfolio, the biopharmaceutical company Aurinia Pharmaceuticals, Inc. has recently announced positive findings from its phase 3 clinical trial of the experimental drug voclosporin, which was…

Continue Reading Lupus Nephritis Patients Should be Excited About the Results of This Phase 3 Trial
FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes
source: pixabay.com

FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes

According to a story from BioPortfolio, Acceleron Pharma and the Bristol-Myers Squibb Company have announced recently that the US Food and Drug Administration (FDA) will review the supplemental Biologics License…

Continue Reading FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes
The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease
source: pixabay.com

The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease

According to a story from Business Wire, the biopharmaceutical company Bristol-Myers Squibb has recently announced that the US Food and Drug Administration (FDA) has granted the company's drug abatacept (marketed…

Continue Reading The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease
FDA Grants Orphan Drug Designation for Treatment of Pancreatic Neuroendocrine Tumors
source: pixabay.com

FDA Grants Orphan Drug Designation for Treatment of Pancreatic Neuroendocrine Tumors

  Surufatinib was recently granted Orphan Drug designation by the FDA. This drug was made for the treatment of pancreatic neuroendocrine tumors (PanNETs). It was created by Hutchison China MediTech…

Continue Reading FDA Grants Orphan Drug Designation for Treatment of Pancreatic Neuroendocrine Tumors
New Center for Research of Primary Sclerosing Cholangitis Created in Boston
Fall is a GREAT time of year to visit Boston--and you feel AWESOME about helping to raise funds for PI! [Source: pixabay.com]

New Center for Research of Primary Sclerosing Cholangitis Created in Boston

Copyscape score: 2% Brigham and Women's is launching the nation's first ever center to conduct research on primary sclerosing cholangitis, a rare liver disease that affects about 30,000 people in…

Continue Reading New Center for Research of Primary Sclerosing Cholangitis Created in Boston

Press Release: Rare Disease Community Calls on Congress & FDA to Enact Life-Saving Public Policy Solutions

Contact: Britta Vander Linden [email protected] 917.604.6518 30 million Americans need more treatment and diagnostic opportunities https://everylifefoundation.org/rare-disease-community-calls-on-congress-fda-to-enact-life-saving-public-policy-solutions/ (Washington, D.C., December 4, 2019) Hundreds of rare disease advocates from around the country were brought to Washington,…

Continue Reading Press Release: Rare Disease Community Calls on Congress & FDA to Enact Life-Saving Public Policy Solutions
ICYMI: #PatientsAreNotFaking Because Patients Are Sick, And They Are Sick of Not Being Taken Seriously
source: pixabay.com

ICYMI: #PatientsAreNotFaking Because Patients Are Sick, And They Are Sick of Not Being Taken Seriously

Getting a diagnosis for a rare disease is hard. Not many people are familiar with the many obscure symptoms and manifestations of these diseases. Because of this, patients with rare…

Continue Reading ICYMI: #PatientsAreNotFaking Because Patients Are Sick, And They Are Sick of Not Being Taken Seriously

After Five Insurance Coverage Denials, the Next Appeal Brought a Young Patient Closer to Receiving Treatment for Metachromatic Leukodystrophy

  A recent article in the Taunton Gazette describes the dilemma faced by the parents of four-year-old Jaxtien Miller who is a metachromatic leukodystrophy patient waiting for a stem cell…

Continue Reading After Five Insurance Coverage Denials, the Next Appeal Brought a Young Patient Closer to Receiving Treatment for Metachromatic Leukodystrophy
Study Finds Increased Risk of Bladder Problems for Primary Sjögren’s Syndrome Patients
source: pixabay.com

Study Finds Increased Risk of Bladder Problems for Primary Sjögren’s Syndrome Patients

A recent study published in the scientific journal PLOS One has determined that patients with the rare disorder primary Sjögren's syndrome are at a greater risk of bladder problems than previously thought.…

Continue Reading Study Finds Increased Risk of Bladder Problems for Primary Sjögren’s Syndrome Patients
CRISPR/Cas9 Looks Promising for Transfusion Dependent Sickle Cell Disease and Beta Thalassemia Patients 
source: pixabay.com

CRISPR/Cas9 Looks Promising for Transfusion Dependent Sickle Cell Disease and Beta Thalassemia Patients 

   CRISPR/Cas9 technology reached another milestone with encouraging results in two recent trials of CTX001. An article in Pharmaceutical Technology carried an announcement by CRISPR Therapeutics and Vertex Pharmaceuticals about…

Continue Reading CRISPR/Cas9 Looks Promising for Transfusion Dependent Sickle Cell Disease and Beta Thalassemia Patients